Clinical Trials · NCT04129255

Octreotide LAR in the Induction of Immunologic Response in NENs Patients

CompletedPhase 2Octreotide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
National Cancer Institute, Naples
Enrollment
34
Start date
Jun 2017
Locations
1 site, Italy
Primary endpoint
Exploring the changes in immune-regulatory cells induced by OCT LAR
View Octreotide compound reference